MedPath

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

271

Active:13
Completed:26

Trial Phases

6 Phases

Early Phase 1:9
Phase 1:48
Phase 2:108
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (245 trials with phase data)• Click on a phase to view related trials

Phase 2
108 (44.1%)
Not Applicable
62 (25.3%)
Phase 1
48 (19.6%)
Phase 4
13 (5.3%)
Early Phase 1
9 (3.7%)
Phase 3
5 (2.0%)

Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

Not Applicable
Not yet recruiting
Conditions
AML, Adult
Interventions
First Posted Date
2025-08-20
Last Posted Date
2025-08-20
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
240
Registration Number
NCT07132684

MRD-positive AML Clinical Study

First Posted Date
2025-08-20
Last Posted Date
2025-08-20
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
120
Registration Number
NCT07131059
Locations
🇨🇳

Blood Diseases Hospital, Tianjin, Tianjin, China

Autologous Hematopoietic Stem Cell Infusion for Prolonged Cytopenia After CAR-T Cell Therapy

Not Applicable
Recruiting
Conditions
Prolonged Cytopenia Following CAR-T Therapy
Interventions
Biological: Autologous hematopoietic stem cell infusion
First Posted Date
2025-08-17
Last Posted Date
2025-08-17
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
20
Registration Number
NCT07127289
Locations
🇨🇳

Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

Effect of a Simplified Mindfulness Intervention on Health-related Quality of Life in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Prospective Single-Center Randomized Controlled Trial

Not Applicable
Not yet recruiting
Conditions
Hematopoietic Stem Cell Transplantation
First Posted Date
2025-08-17
Last Posted Date
2025-08-17
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
148
Registration Number
NCT07127562

The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT

Not Applicable
Recruiting
Conditions
AML (Acute Myelogenous Leukemia)
AML
Interventions
First Posted Date
2025-08-17
Last Posted Date
2025-08-17
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
10
Registration Number
NCT07126782
Locations
🇨🇳

Institute of Hematology & Blood Diseases Hospital, Beijing, China

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 55
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.